# US 2023/0055741 A1 · Functionalized heterocyclic compounds as modulators of stimulator of interferon genes (sting)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055741 A1
- Document ID: US20230055741A1
- Status: Published application
- Kind: A1
- Application number: 17/783,940
- Filed: 2020-12-11
- Published: 2023-02-23
- Earliest claimed: 2019-12-11
- Assignees: Ryvu Therapeutics S.A.
- Applicants: Ryvu Therapeutics S.A.
- Inventors: Magdalena Izabela ZAWADZKA; Luigi Piero STASI; Maciej Krzysztof ROGACKI; Grzegorz Wojciech CWIERTNIA; Lukasz Piotr DUDEK; Agnieszka Justyna GIBAS; Anna RAJDA; Charles-Henry FABRITIUS; Adam RADZIMIERSKI; Tushar Ravindra MAHAJAN; Marcin Wojciech LES; Karol ZUCHOWICZ; Marek WRONOWSKI; David Jörg SYNAK; Sundara Raghuram TANGIRALA
- Web page: https://patentgrep.com/patent/US20230055741A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07B 2200/07: Optical isomers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).

## Claims

### Claim 1

A compound-linker construct comprising
(i) a compound of formula (I); and
(ii) a linker L1
wherein the compound of formula (I) is a compound of the following formula
or a salt, stereoisomer, tautomer, or N-oxide thereof,
wherein
X1 is CH or N;
X2 is CR3 or N;
R1, R2 and R3 are independently H, OH, NRCRD, CN, halogen, C1-C4-alkyl, NRCRD—C1-C4-alkyl, C1-C4-alkoxy, aryloxy, benzyloxy, C(═O)RE, NRFC(═O)RE, NRF—(C1-C4-alkylene) C(═O)RE, NRF—(C1-C4-alkylene)-NRCRD, O—(C1-C4-alkylene)-NRCRD, or 4- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, carbocyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyloxy, or heterocyclyl-C1-C2-alkyl, or 8- to 10-membered saturated, partially or fully unsaturated, or aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R4 is a 5- or 6-membered aromatic carbocyclic or heterocyclic ring, or a 9- or 10-membered aromatic carbobicyclic or heterobicyclic ring, wherein the heterocyclic or heterobicyclic ring comprises at least one nitrogen atom and optionally one or more, same or different additional heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned cyclic rings is independently unsubstituted or substituted with one or more same or different substituents RX;
R5 is a 5- or 6-membered saturated heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom is independently unsubstituted or substituted with one or more, same or different substituents RY;
and wherein
RN is H, C1-C4-alkyl, HO(C═O)—C1-C4-alkyl, NRCRD—C1-C4-alkyl, C1-C2-alkoxy-C1-C4-alkyl, or a 3- or 4-membered saturated carbocyclyl or heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
RC and RD are independently H, or C1-C2-alkyl; or
RC and RD together with the nitrogen atom to which they are bonded form a 5- or 6-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RX;
RE is H, C1-C2-alkyl, NRCRD—C1-C4-alkyl, phenyl, benzyl, ORG, or NRHRI; or a 5- or 6-membered saturated, partially or fully unsaturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RF;
RF is H, C1-C2-alkyl, C3-C6-cycloalkyl, phenyl, benzyl, or C(═O)NRHRI;
RG is H, C1-C2-alkyl, or 5- or 6-membered aromatic carbocyclyl, carbocyclyl-C1-C2alkyl, heterocyclyl, or heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N-atoms are independently oxidized or non-oxidized;
RH and RI are independently H, C1-C2-alkyl, or 5- or 6-membered aromatic carbocyclyl, carbocyclyl-C1-C2-alkyl, heterocyclyl, or heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N-atoms are independently oxidized or non-oxidized; or
RH and RI together with the nitrogen atom to which they are bonded form a 5- or 6-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RX;
RX is OH, NRCRD, halogen, CN, NO2, C1-C2-alkyl, C1-C2haloalkyl, NRCRD—C1-C4-alkyl, RCO—C1-C4-alkyl, C1-C2alkoxy, C(═O)RE, or two RX form ═O, or two RX together with the carbon atom to which they are bonded form a 3- to 5-membered saturated, partially or fully unsaturated, or aromatic carbocyclic ring;
RY is halogen, CN, OH, C1-C2-alkyl, HO—C1-C2alkyl, C3-C6-cycloalkyl, C1-C2alkoxy, NRCRD, S(═O)2NRCRD, C(═O)RE, or 5- or 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, carbocyclyl-C1-C2alkyl, heterocyclyl, and heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or two RY form ═O; or two RY attached to identical or neighboring carbon atoms may form a 3-membered carbocyclic ring;
with the proviso that
either
any one of
R1, R2, or R3 is NRCRD, NRCRD—C1-C4-alkyl, NRF—(C1-C4-alkylene)-NRCRD, O—(C1-C4-alkylene)-NRCRD, or 8- to 10-membered saturated, partially or fully unsaturated, or aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
or
any one of
R1, R2, or R3 is NRFC(═O)RE, wherein RE is NRCRD—C1-C4-alkyl;
or
RN is NRCRD—C1-C4-alkyl, or C1-C2-alkoxy-C1-C4-alkyl;
or
any one of the substituents R1, R2, R3, R4, R5, RN carries a substituent RX, wherein
RX is OH, NRCRD, NRCRD—C1-C4-alkyl, or RCO—C1-C4-alkyl.

### Claim 2 (depends on 1)

The compound-linker construct according to claim 1, wherein a covalent bond between the compound of formula (I) and the linker L1 is established by the reaction of a functional group of the compound of formula (I) with a functional group handle of the linker LI; and wherein preferably the functional group of the compound of formula (I) is attached to or part of the substituents R2, R4, R5, or RN so that the linker L1 will be covalently bonded to the compound of formula (I) according to any one of the following structures:

### Claim 3 (depends on 1, 2)

The compound-linker construct according to claim 1 or 2, wherein the linker L1 comprises
(i) a chain LC of 2 to 100 atoms selected from carbon, nitrogen, oxygen, and sulfur atoms, which may be interrupted by 5- to 10-membered aryl and heteroaryl groups and/or 3- to 8-membered saturated carbocyclyl or heterocyclyl groups, wherein the aforementioned heteroaryl and heterocyclic groups comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the chain is independently unsubstituted or substituted with one or more same or different substituents selected from halogen, OH, ═O, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6-haloalkoxy;
and preferably
a chain LC of units selected from a linear or branched polyethylene glycol chain, a sequence of amino acids, and a linear or branched C1-C10-alkyl chain, wherein each substitutable carbon or heteroatom of the afore mentioned units may be unsubstituted or substituted with one or more, same or different substituents selected from halogen, OH, ═O, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6haloalkoxy;
(ii) a functional group handle H1A, which is covalently bonded to the compound of formula (I);
(iii) a functional group handle H1B suitable for forming a covalent bond to a targeting moiety T.

### Claim 4 (depends on 1, 2, 3)

The compound-linker construct according to any one of claims 1 to 3, wherein the linker L1 has the structure H1A-LC-H1B and is selected from the group consisting of:
wherein
LC is a chain LC of units selected from a linear or branched polyethylene glycol chain, a sequence of amino acids, and a linear or branched C1-C10-alkyl chain, wherein each substitutable carbon or heteroatom of the afore mentioned units may be unsubstituted or substituted with one or more, same or different substituents selected from halogen, OH, ═O, C1-C2-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6-haloalkoxy; and
§ marks the connection to the compound of formula (I); and
X represents a leaving group selected from
and wherein preferably LC is selected from group consisting of
wherein n is 0, 1, 2, 3, 4, 5, 6, 7, or 8.

### Claim 5 (depends on 1, 2, 3, 4)

The compound-linker construct according to any one of claims 1 to 4, wherein the linker L1 is selected from the group consisting of:
wherein
§ marks the connection to the compound of formula (I).

### Claim 6

A conjugate comprising
(i) a compound of formula (I);
(ii) a linker L2; and
(iii) a targeting moiety T
wherein the compound of formula (I) is a compound of the following formula
or a salt, stereoisomer, tautomer, or N-oxide thereof,
wherein
X1 is CH or N;
X2 is CR3 or N;
R1, R2 and R3 are independently H, OH, NRCRD, CN, halogen, C1-C4-alkyl, NRCRD—C1-C4-alkyl, C1-C4-alkoxy, aryloxy, benzyloxy, C(═O)RE, NRFC(═O)RE, NRF—(C1-C4-alkylene) C(═O)RE, NRF—(C1-C4-alkylene)-NRCRD, O—(C1-C4-alkylene)-NRCRD, or 4- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, carbocyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyloxy, or heterocyclyl-C1-C2alkyl, or 8- to 10-membered saturated, partially or fully unsaturated, or aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R4 is a 5- or 6-membered aromatic carbocyclic or heterocyclic ring, or a 9- or 10-membered aromatic carbobicyclic or heterobicyclic ring, wherein the heterocyclic or heterobicyclic ring comprises at least one nitrogen atom and optionally one or more, same or different additional heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned cyclic rings is independently unsubstituted or substituted with one or more same or different substituents RX;
R5 is a 5- or 6-membered saturated heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom is independently unsubstituted or substituted with one or more, same or different substituents RY;
and wherein
RN is H, C1-C4-alkyl, HO(C═O)—C1-C4-alkyl, NRCRD—C1-C4-alkyl, C1-C2-alkoxy-C1-C4-alkyl, or a 3- or 4-membered saturated carbocyclyl or heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
RC and RD are independently H, or C1-C2-alkyl; or
RC and RD together with the nitrogen atom to which they are bonded form a 5- or 6-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RX;
RE is H, C1-C2-alkyl, NRCRD—C1-C4-alkyl, phenyl, benzyl, ORG, or NRHRI; or a 5- or 6-membered saturated, partially or fully unsaturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RF;
RF is H, C1-C2-alkyl, C3-C6-cycloalkyl, phenyl, benzyl, or C(═O)NRHRI;
RG is H, C1-C2-alkyl, or 5- or 6-membered aromatic carbocyclyl, carbocyclyl-C1-C2alkyl, heterocyclyl, or heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N-atoms are independently oxidized or non-oxidized;
RH and RI are independently H, C1-C2-alkyl, or 5- or 6-membered aromatic carbocyclyl, carbocyclyl-C1-C2-alkyl, heterocyclyl, or heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N-atoms are independently oxidized or non-oxidized; or
RH and RI together with the nitrogen atom to which they are bonded form a 5- or 6-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RX;
RX is OH, NRCRD, halogen, CN, NO2, C1-C2-alkyl, C1-C2haloalkyl, NRCRD—C1-C4-alkyl, RCO—C1-C4-alkyl, C1-C2alkoxy, C(═O)RE, or two RX form ═O, or two RX together with the carbon atom to which they are bonded form a 3- to 5-membered saturated, partially or fully unsaturated, or aromatic carbocyclic ring;
RY is halogen, CN, OH, C1-C2-alkyl, HO—C1-C2alkyl, C3-C6-cycloalkyl, C1-C2alkoxy, NRCRD, S(═O)2NRCRD, C(═O)RE, or 5- or 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, carbocyclyl-C1-C2alkyl, heterocyclyl, and heterocyclyl-C1-C2alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or two RY form ═O; or two RY attached to identical or neighboring carbon atoms may form a 3-membered carbocyclic ring;
with the proviso that
either
any one of
R1, R2, or R3 is NRCRD, NRCRD—C1-C4-alkyl, NRF—(C1-C4-alkylene)-NRCRD, O—(C1-C4-alkylene)-NRCRD, or 8- to 10-membered saturated, partially or fully unsaturated, or aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
or
any one of
R1, R2, or R3 is NRFC(═O)RE, wherein RE is NRCRD—C1-C4-alkyl;
or
RN is NRCRD—C1-C4-alkyl, or C1-C2-alkoxy-C1-C4-alkyl;
or
any one of the substituents R1, R2, R3, R4, R5, RN carries a substituent RX, wherein
RX is OH, NRCRD, NRCRD—C1-C4-alkyl, or RCO—C1-C4-alkyl.

### Claim 7 (depends on 6)

The conjugate according to claim 6, wherein a covalent bond between the compound of formula (I) and the linker L2 is established by the reaction of a functional group of the compound of formula (I) with a functional group handle of the linker L2 and wherein a covalent bond between the targeting moiety T and the linker L2 is established by the reaction of a functional group of the targeting moiety T with a functional group handle of the linker L2; and wherein preferably the functional group of the compound of formula (I) is attached to or part of the substituents R2, R4, R5, or RN so that the linker L2, to which the targeting moiety is covalently bonded on one end, will on the other end be covalently bonded to the compound of formula (I) according to any one of the following structures:

### Claim 8 (depends on 6, 7)

The conjugate according to claim 6 or 7, wherein the linker L2 comprises
(i) a chain LC of 2 to 100 atoms selected from carbon, nitrogen, oxygen, and sulfur atoms, which may be interrupted by 5- to 10-membered aryl and heteroaryl groups and/or 3- to 8-membered saturated carbocyclyl or heterocyclyl groups, wherein the aforementioned heteroaryl and heterocyclic groups comprise one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the chain is independently unsubstituted or substituted with one or more same or different substituents selected from halogen, OH, ═O, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6-haloalkoxy;
and preferably
a chain LC of units selected from a linear or branched polyethylene glycol chain, a sequence of amino acids, and a linear or branched C1-C10-alkyl chain, wherein each substitutable carbon or heteroatom of the afore mentioned units may be unsubstituted or substituted with one or more, same or different substituents selected from halogen, OH, ═O, C1-C5-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6haloalkoxy;
(ii) a functional group handle H1A, which is covalently bonded to the compound of formula (I);
(iii) a functional group handle H2B, which is covalently bonded to the targeting moiety T.

### Claim 9 (depends on 6, 7, 8)

The conjugate according to any one of claims 6 to 8, wherein the linker L2 has the structure H1A-LC-H2B and is selected from the group consisting of:
wherein
LC is a chain LC of units selected from a linear or branched polyethylene glycol chain, a sequence of amino acids, and a linear or branched C1-C10-alkyl chain, wherein each substitutable carbon or heteroatom of the afore mentioned units may be unsubstituted or substituted with one or more, same or different substituents selected from halogen, OH, ═O, C1-C2-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, and C1-C6-haloalkoxy;
§ marks the connection to the compound of formula (I); and
$ marks the connection to the targeting moiety T.
and wherein preferably LC is selected from the group consisting of
wherein n is 0, 1, 2, 3, 4, 5, 6, 7, or 8.

### Claim 10 (depends on 6, 7, 8, 9)

The conjugate of any one of claims 6 to 9, wherein the targeting moiety T comprises an antibody, an antibody fragment, a nucleic acid based molecule, a carbohydrate, a peptide, or a modified peptide, in particular an antibody or an antigen-binding fragment, which is designed to target the Human Epidermal Growth Factor Receptor (EGFR), a plasminogen activator, a cytotoxic T-lymphocyte associated antigen (CTLA) such as CTLA-4, PD-1, PD-L1, KIR, TIM3, VISTA, TIGIT, LAG3, OX40, ROR1, ROR2, vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR), platelet-derived growth factor (PDGF), transforming growth factor (TGF), neurotrophic factors, a nerve growth factor, platelet-derived growth factor (PDGF), interleukin receptors, transforming growth factor (TGF), estrogen receptor, progesterone receptor, c-Kit, cMET, ErbB2/Her2, ErbB3/Her3, ErbB4/Her4, CD3, CD20, CD22, CD30, CD33, CD40, CD47, CD79, CD123, CD133, CD166, CD137, the mesothelin protein, EpCAM, FLT3, PSMA, PSCA, STEAP, CEA, folate receptor, the CD39/CD73 receptors, adenosine receptors, SLC34A2 gene product, the EphA2 tyrosine kinase, the Muc1/Muc16 cell-surface antigens, ALK, AFP, bcr-Abl, PAP.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound-linker construct of any one of claims 1 to 5, or the conjugate of any one of claims 6 to 10, wherein the functional group of the compound of formula (I), which is attached to or part of the substituents R2, R4, R5, or RN, and which forms the covalent bond to the functional group handle H1A of the linker L1 or L2, is selected from the following options:
either
R2 is NHRD, NHRD—C1-C4-alkyl, NH—(C1-C4-alkylene)-NRCRD, NRF—(C1-C4-alkylene)-NHRD, O—(C1-C4-alkylene)-NHRD, or 8- to 10-membered saturated heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises at least one nitrogen atom and optionally one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
or
R2 is NRFC(═O)RE, wherein RE is NHRD—C1-C4-alkyl;
or
RN is NHRD—C1-C4-alkyl;
or
any one of the substituents R2, R4, R5, RN carries a substituent RX, wherein
RX is OH, NHRD, NHRD—C1-C4-alkyl, or HO—C1-C4-alkyl;
and preferably
either
R2 is NH2, NH2—C1-C2-alkyl, NH—(C1-C3-alkylene)-NH2, NH—(C1-C3-alkylene)-NHCH3, NH—(C1-C3-alkylene)-N(CH3)2, O—(C1-C3-alkylene)-NH2, or O—(C1-C3-alkylene)-NHCH3;
or
R2 is NHC(═O)RE, wherein RE is NH2—C1-C4-alkyl;
or
RN is NH2—C1-C3-alkyl;
or
any one of the substituents R2, R4, or R5 carries a substituent RX, wherein RX is OH, NH2, NHCH3, NH2—C1-C2-alkyl, or HO—C1-C2-alkyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound-linker construct of any one of claims 1 to 5 or 11, or the conjugate of any one of claims 6 to 10 or 11, wherein in the compound of formula (I)
X1 is CH;
X2 is CR3 with R3 being H;
R1 is H or F;
R2 is H, OH, NRCRD, CN, halogen, NRCRD—C1-C4-alkyl, NRFC(═O)RE, NRF—(C1-C4-alkylene) C(═O)RE, NRF—(C1-C4-alkylene)-NRCRD, O—(C1-C4-alkylene)-NRCRD, or 4- to 6-membered saturated heterocyclyl, or 8- to 10-membered saturated heterobicyclyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise a nitrogen atom and optionally one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R4 is pyridinyl, wherein each substitutable carbon atom in the cyclic ring is independently unsubstituted or substituted by one or more, same or different substituents RX;
R5 is piperidine, wherein each substitutable carbon or heteroatom in the piperidine ring is independently unsubstituted or substituted by one or more, same or different substituents RY; and
RN is H, C1-C4-alkyl, HO(C═O)—C1-C3-alkyl, NHRD—C1-C6-alkyl, C1-C2alkoxy-C1-C6-alkyl, or cyclopropyl;
wherein preferably
RC is H or C1-C2-alkyl;
RD is H or C1-C2-alkyl;
RE is NH2—C1-C4-alkyl;
RF is H;
RX is halogen, OH, NH2, NHCH3, C1-C2-alkyl, C1-C2alkoxy, NH2—C1-C2-alkyl, HO—C1-C2-alkyl, or two RX together with the carbon atom to which they are bonded form a 3-membered saturated carbocyclic ring;
RY is halogen, OH, NH2, or a 5- or 6-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N or S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
with the proviso that
either
R2 is NH2, NH2—C1-C2-alkyl, NH—(C1-C3-alkylene)-NH2, NH—(C1-C3-alkylene)-NHCH3, NH—(C1-C3-alkylene)-N(CH3)2, O—(C1-C3-alkylene)-NH2, or O—(C1-C3-alkylene)-NHCH3;
or
R2 is NHC(═O)RE, wherein RE is NH2—C1-C4-alkyl;
or
RN is NH2—C1-C3-alkyl;
or
any one of the substituents R2, R4, or R5 carries a substituent RX, wherein
RX is OH, NH2, NHCH3, NH2—C1-C2-alkyl, or HO—C1-C2alkyl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A pharmaceutical composition comprising a pharmaceutically effective amount of the compound-linker construct of any one of claims 1 to 5, 11 or 12, or the conjugate of any one of claims 6 to 10, 11 or 12 and optionally a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A compound-linker construct of any one of claims 1 to 5, 11 or 12, or the conjugate of any one of claims 6 to 10, 11 or 12, or a pharmaceutical composition according to claim 13 for use in medicine.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A compound-linker construct of any one of claims 1 to 5, 11 or 12, or the conjugate of any one of claims 6 to 10, 11 or 12, or a pharmaceutical composition according to claim 13 for use in the treatment of a disease selected from the group consisting of cancer, pre-cancerous syndromes, and infectious diseases; or for use in an immunogenic composition or as vaccine adjuvant.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A compound-linker construct of any one of claims 1 to 5, 11 or 12, or the conjugate of any one of claims 6 to 10, 11 or 12, or a pharmaceutical composition according to claim 13 for use in the treatment of a disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases.
